Influence of subject discontinuation on long-term nonvertebral fracture rate in the denosumab FREEDOM Extension study - Wikidata - awgldk - TriplyDB

Influence of subject discontinuation on long-term nonvertebral fracture rate in the denosumab FREEDOM Extension study

Influence of subject discontinuation on long-term nonvertebral fracture rate in the denosumab FREEDOM Extension study

http://www.wikidata.org/entity/Q33612987

about

Influence of subject discontinuation on long-term nonvertebral fracture rate in the denosumab FREEDOM Extension study

http://www.wikidata.org/entity/Q33612987

description

2017 nî lūn-bûn

@nan

2017 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2017 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

name

Influence of subject discontin ...... osumab FREEDOM Extension study

@ast

Influence of subject discontin ...... osumab FREEDOM Extension study

@en

type

label

Influence of subject discontin ...... osumab FREEDOM Extension study

@ast

Influence of subject discontin ...... osumab FREEDOM Extension study

@en

prefLabel

Influence of subject discontin ...... osumab FREEDOM Extension study

@ast

Influence of subject discontin ...... osumab FREEDOM Extension study

@en

P1433

Q33612987-1BA99B1E-78C7-4CA5-8339-C1B7CA394950

P1476

Q33612987-B89A4EE9-ABDD-4A16-87BD-000370DCAE42

P2093

Q33612987-2ADD2236-EA95-4218-8352-3D699315F05E

Q33612987-451A3783-B945-4727-98FC-F490EDC2BD7A

Q33612987-4D1F1FE0-7410-4DE5-9BDF-E621B9E23AE6

Q33612987-64CA929F-E881-49A3-87E4-C8C8A0B30550

Q33612987-7419E92F-1F2B-49E1-B1D3-5BD7674DCB06

Q33612987-7B83E054-8023-47C1-B6DB-E76C1A4F6557

Q33612987-7BA5C633-2864-4500-84AC-7802B7A22690

Q33612987-7C495192-9448-4FEC-8B64-8DA2453EB62F

Q33612987-82E250F2-3315-4190-BE17-5495AA18E9F9

Q33612987-A6AD8EC1-4633-4028-A093-7757D91BC7D9

P2860

Q33612987-00CB1F60-E8BC-454D-8714-025443F24ABB

Q33612987-0360A637-CFBF-4AC8-B8C5-899B03BB0EF4

Q33612987-20A5C492-689D-42B5-8883-FA767BEA75A6

Q33612987-7210BE93-0812-459D-8F84-683B1E72A694

Q33612987-79FBF1B1-B12E-494A-AC1A-CD4E4D5F6764

Q33612987-A577F584-BFDB-47A7-9879-1316345C870F

Q33612987-A6C0B240-381F-4BBF-9C22-7B2EFD62C7BB

Q33612987-D8CECC3D-946F-4C90-AA35-94FA6D20FC7C

P2888

Q33612987-50C4CAC1-8F67-411D-84F5-6F38D7A563B3

P304

Q33612987-F5BE6457-42F0-461B-9CCA-8B0B7B37C9D0

P31

Q33612987-A83006BE-8F5E-456C-840C-A273897D4908

P356

Q33612987-5560FD42-FE4D-4678-B0DC-B1260648D4DB

P433

Q33612987-6053E510-DC49-49EB-8409-13BCB34DE64A

P478

Q33612987-7B31A10C-1D7A-4695-A997-8575B78DD0E8

P577

Q33612987-4755639F-2C21-4AE3-92E3-392CD03A690D

P6179

Q33612987-B1ABA737-5855-42D1-B556-8F1E81EB2A14

P698

Q33612987-BD7CDB38-D34E-4572-A8F8-7EBB3342301F

P932

Q33612987-A1558270-8374-4ECE-898E-B511ABBEE519

P356

S12891-017-1520-6

P1433

BMC Musculoskeletal Disorders

P1476

Influence of subject discontin ...... osumab FREEDOM Extension study

@en

P2093

Andrea Wang

http://www.w3.org/2001/XMLSchema#string

Celia J F Lin

http://www.w3.org/2001/XMLSchema#string

Chris Recknor

http://www.w3.org/2001/XMLSchema#string

Henry G Bone

http://www.w3.org/2001/XMLSchema#string

Jonathan D Adachi

http://www.w3.org/2001/XMLSchema#string

Michael A Bolognese

http://www.w3.org/2001/XMLSchema#string

Nadia S Daizadeh

http://www.w3.org/2001/XMLSchema#string

Paula Dakin

http://www.w3.org/2001/XMLSchema#string

Peyman Hadji

http://www.w3.org/2001/XMLSchema#string

Rachel B Wagman

http://www.w3.org/2001/XMLSchema#string

P2860

Denosumab for prevention of fractures in postmenopausal women with osteoporosis

A multiple imputation method for sensitivity analyses of time-to-event data with possibly informative censoring.

The effect of three or six years of denosumab exposure in women with postmenopausal osteoporosis: results from the FREEDOM extension

Relationship between bone mineral density changes with denosumab treatment and risk reduction for vertebral and nonvertebral fractures.

Five years of denosumab exposure in women with postmenopausal osteoporosis: results from the first two years of the FREEDOM extension.

Further reductions in nonvertebral fracture rate with long-term denosumab treatment in the FREEDOM open-label extension and influence of hip bone mineral density after 3 years

The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study

Estimating long-term effects of treatment from placebo-controlled trials with an extension period, using virtual twins.

P2888

s12891-017-1520-6

P304

174

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/S12891-017-1520-6

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

18

http://www.w3.org/2001/XMLSchema#string

P577

2017-04-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1084955864

http://www.w3.org/2001/XMLSchema#string

P698

28449657

http://www.w3.org/2001/XMLSchema#string

P932

5408481

http://www.w3.org/2001/XMLSchema#string